Cardiac Biomarkers Market to Grow with a CAGR of 7.36% through 2029
Surge in research and development activities is expected to drive the Global
Cardiac Biomarkers Market growth in the forecast period, 2025-2029.
According to TechSci Research report, “Cardiac
Biomarkers Market - Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2029F”, the Global Cardiac Biomarkers Market
stood at USD 16.31 Billion in 2023 and is anticipated to grow with a CAGR of 7.36%
through 2029. Initiatives taken by government based on cardiac biomarkers has
led to favorable market conditions for the Global Cardiac Biomarkers Market.
Several factors contribute to the growth of various cardiac biomarkers products.
Governments are actively involved in promoting
awareness about cardiovascular diseases and the importance of early detection
through public health campaigns. These initiatives aim to educate the
population about risk factors such as hypertension, obesity, and smoking, which
contribute to the development of CVDs. By raising awareness, governments seek
to encourage individuals to undergo regular health screenings, including tests
for cardiac biomarkers like BNP and NT-proBNP, to facilitate early diagnosis
and timely intervention.
Investments in healthcare infrastructure are essential
for expanding access to cardiac biomarker testing and diagnostic services,
particularly in underserved and rural communities. Governments allocate
resources to upgrade laboratory facilities, train healthcare personnel in
biomarker testing methodologies, and deploy point-of-care testing devices.
These initiatives aim to reduce disparities in healthcare access, improve early
disease detection rates, and optimize cardiovascular disease management
outcomes nationwide.
Governments collaborate with international
organizations, such as the World Health Organization (WHO) and the World Heart
Federation (WHF), to address global challenges in cardiovascular health. These
partnerships facilitate knowledge sharing, capacity building in biomarker
testing, and harmonization of cardiovascular health policies across borders. By
leveraging international expertise and resources, governments strengthen their
efforts to combat cardiovascular diseases and promote sustainable healthcare
systems worldwide.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Cardiac Biomarkers Market”
R&D activities in the field of cardiac biomarkers
have led to significant advancements in cardiovascular diagnostics,
transforming the landscape of CVD management. Biomarkers such as troponin,
CK-MB, and BNP play crucial roles in diagnosing acute coronary syndromes (ACS),
heart failure, and other cardiac conditions. Ongoing research focuses on
enhancing the sensitivity, specificity, and predictive value of these
biomarkers, enabling earlier detection of cardiac damage and more accurate risk
assessment for adverse cardiovascular events.
One of the key outcomes of R&D efforts in cardiac
biomarkers is the development of high-sensitivity assay technologies.
High-sensitivity troponin assays, for instance, detect minor elevations in
troponin levels that may indicate subtle myocardial injury, allowing for early
intervention and improved patient outcomes. These advancements in assay
sensitivity have revolutionized ACS diagnosis and risk stratification,
facilitating timely treatment decisions and optimizing patient care pathways.
R&D activities in cardiac biomarkers continue to
drive innovation in biomarker discovery and validation. Researchers are
exploring novel biomarkers associated with cardiovascular pathophysiology,
inflammation, oxidative stress, and genetic predisposition to CVDs. These
efforts expand the biomarker repertoire, offering new tools for diagnosing and
monitoring cardiovascular health and enabling early detection of disease
progression.
The Global Cardiac Biomarkers Market is segmented into
type, application, regional distribution, and company.
Based on Type, Troponin have emerged as
the dominating segment in the Global Cardiac Biomarkers Market in 2023. Troponin,
specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), are
proteins released into the bloodstream when heart muscle cells are damaged,
such as during a heart attack. The sensitivity and specificity of troponin
assays in detecting myocardial injury surpass those of traditional biomarkers
like creatine kinase-MB (CK-MB) and myoglobin. This superior diagnostic
accuracy enables healthcare providers to swiftly and accurately diagnose acute
myocardial infarction (heart attack), guiding timely interventions and
improving patient outcomes.
Troponin assays have become the gold
standard for diagnosing acute coronary syndromes (ACS), including myocardial
infarction. International clinical guidelines, such as those from the American
College of Cardiology (ACC) and the European Society of Cardiology (ESC),
recommend troponin testing as an integral part of evaluating patients
presenting with chest pain or other symptoms suggestive of ACS. This
endorsement has cemented troponin's place as a cornerstone in cardiac care
protocols globally, driving its widespread adoption in hospital settings.
Advancements in assay technologies have
significantly contributed to troponin's dominance in the market. Highly
sensitive troponin assays (hs-cTn) have been developed, capable of detecting
minute quantities of troponin in the bloodstream with greater precision and
reliability. These advancements have not only enhanced diagnostic accuracy but
also facilitated the early detection of myocardial injury, allowing for prompt
initiation of appropriate treatments and interventions.
Troponin's dominance in the global
cardiac biomarkers market is also influenced by market dynamics and competitive
forces. Major diagnostic companies and healthcare institutions invest heavily
in troponin research and development, aiming to enhance assay sensitivity,
reduce turnaround times, and improve overall performance. This competitive
landscape drives innovation and technological advancements, further solidifying
troponin's position as the preferred biomarker for assessing cardiac health.
Based on Region, Asia Pacific have emerged as the fastest
growing region in the Global Cardiac Biomarkers Market in 2023. One of the
primary drivers of Asia Pacific's growth in the global cardiac biomarkers
market is the region's expanding healthcare infrastructure and improving access
to healthcare services. Economic growth in countries like China, India, and
Southeast Asian nations has spurred investments in healthcare facilities,
medical technologies, and diagnostic capabilities. This infrastructure
development facilitates greater adoption of advanced cardiac biomarker testing
technologies, enhancing early detection, diagnosis, and management of
cardiovascular diseases (CVDs).
Asia Pacific faces a significant burden of
cardiovascular diseases, attributed to factors such as urbanization, sedentary
lifestyles, dietary changes, and an aging population. The prevalence of
conditions like coronary artery disease, hypertension, and stroke is on the
rise, necessitating effective strategies for disease prevention, early
detection, and treatment. Cardiac biomarkers play a crucial role in these
efforts by providing insights into heart function, damage, and disease
progression, thereby supporting timely interventions and personalized treatment
approaches.
Greater awareness about cardiovascular health and the
benefits of early detection has spurred demand for cardiac biomarker testing
among healthcare providers and patients in Asia Pacific. Educational campaigns,
disease awareness programs, and medical conferences highlight the importance of
preventive healthcare measures and regular health screenings. As a result,
healthcare professionals and patients are increasingly recognizing the role of
biomarkers in identifying cardiac risks, monitoring treatment responses, and
improving clinical outcomes.
Major companies operating in Global Cardiac Biomarkers
Market are:
- Abbott Laboratories Inc.
- QuidelOrtho Corporation
- Siemens Healthineers AG
- F. Hoffmann-La Roche Ltd
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Randox Laboratories Ltd.
- Creative Diagnostics
- Life Diagnostics Inc.
- BIOMÉRIEUX Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“Nanotechnology facilitates multiplexed biomarker
detection, allowing simultaneous analysis of multiple cardiac biomarkers in a
single sample. This capability is crucial for comprehensive cardiovascular
disease profiling, as it provides clinicians with a holistic view of a
patient's cardiac health status. Multiplexed assays reduce the turnaround time
for diagnostic testing, enhance efficiency in clinical laboratories, and
support personalized treatment strategies based on individual biomarker
profiles”, said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Cardiac Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global
Cardiac Biomarkers Market and provides statistics & information on market
size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Cardiac
Biomarkers Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com